8.40

2.21% -0.19

After Hours: 8.39 -0.010 -0.12%

Xilio Therapeutics Inc (XLO)

Overview News Price History Financials Discussions Forecast

Xilio Therapeutics Inc stock is traded at $8.40, with a volume of 36,060. It is down -2.21% in the last 24 hours and up +17.62% over the past month. Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

Previous Close:

$8.59

Open:

$8.57

24h Volume:

36,060

Relative Volume:

0.95

Market Cap:

$48.57M

Revenue:

$43.77M

Net Income/Loss:

$-35.04M

P/E Ratio:

-2.5829

EPS:

-3.2521

Net Cash Flow:

$-5.51M

1W Performance:

-3.34%

1M Performance:

+17.62%

6M Performance:

-24.05%

1Y Performance:

-15.73%

1-Day Range:

$8.33

$8.74

1-Week Range:

$8.3185

$8.899

52-Week Range:

$6.4652

$16.52

Xilio Therapeutics Inc Stock (XLO) Company Profile

Name

Xilio Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

617-833-1027

Address

828 WINTER STREET, WALTHAM

Employee

Twitter

Next Earnings Date

2026-03-24

Latest SEC Filings

XLO's Discussions on Twitter

Compare XLO vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XLO Xilio Therapeutics Inc	8.40	49.67M	43.77M	-35.04M	-5.51M	-3.2521
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-06-25	Initiated	Leerink Partners	Outperform
Dec-21-22	Initiated	Chardan Capital Markets	Buy
Jan-10-22	Initiated	H.C. Wainwright	Buy
Nov-16-21	Initiated	Cowen	Outperform
Nov-16-21	Initiated	Guggenheim	Buy
Nov-16-21	Initiated	Morgan Stanley	Overweight
Nov-16-21	Initiated	Raymond James	Outperform

View All

Xilio Therapeutics Inc Stock (XLO) Latest News

Apr 13, 2026

Levels Update: Is Xilio Therapeutics Inc attractive for institutional investorsRate Hike & Risk Managed Investment Signals - baoquankhu1.vn

Apr 13, 2026

Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting - ADVFN

Apr 13, 2026

Apr 12, 2026

Certain Pre-Funded Warrants of Xilio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-APR-2026. - marketscreener.com

Apr 12, 2026

Certain Common Stock of Xilio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-APR-2026. - marketscreener.com

Apr 12, 2026

Apr 10, 2026

XLO Should I Buy - Intellectia AI

Apr 10, 2026

Apr 09, 2026

Energy Moves: What is the long term forecast for Xilio Therapeutics Inc stockEarnings Beat & Reliable Breakout Forecasts - baoquankhu1.vn

Apr 09, 2026

Apr 04, 2026

Surprises Report: How cyclical is Xilio Therapeutics Incs revenue streamQuarterly Investment Review & Real-Time Stock Entry Alerts - baoquankhu1.vn

Apr 04, 2026

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm

Apr 04, 2026

Apr 03, 2026